%0 Journal Article
%T Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.
%A Brasó-Maristany F
%A Ferrero-Cafiero JM
%A Falato C
%A Martínez-Sáez O
%A Cejalvo JM
%A Margelí M
%A Tolosa P
%A Salvador-Bofill FJ
%A Cruz J
%A González-Farré B
%A Sanfeliu E
%A Òdena A
%A Serra V
%A Pardo F
%A Luna Barrera AM
%A Arumi M
%A Guerra JA
%A Villacampa G
%A Sánchez-Bayona R
%A Ciruelos E
%A Espinosa-Bravo M
%A Izarzugaza Y
%A Galván P
%A Matito J
%A Pernas S
%A Vidal M
%A Santhanagopal A
%A Sellami D
%A Esker S
%A Fan PD
%A Suto F
%A Vivancos A
%A Pascual T
%A Prat A
%A Oliveira M
%J Nat Commun
%V 15
%N 1
%D 2024 Jul 11
%M 38992028
%F 17.694
%R 10.1038/s41467-024-50056-y
%X Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd's response in women with early-stage hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer. In the SOLTI-1805 TOT-HER3 trial, a single HER3-DXd dose was administered to 98 patients across two parts: 78 patients received 6.4 mg/kg (Part A), and 44 received a lower 5.6 mg/kg dose (Part B). The CelTIL score, measuring tumor cellularity and infiltrating lymphocytes from baseline to day 21, was used to assess drug activity. Part A demonstrated increased CelTIL score after one dose of HER3-DXd. Here we report CelTIL score and safety for Part B. In addition, the exploratory analyses of part A involve a comprehensive study of gene expression, somatic mutations, copy-number segments, and DNA-based subtypes, while Part B focuses on validating gene expression. RNA analyses show significant correlations between CelTIL responses, high proliferation genes (e.g., CCNE1, MKI67), and low expression of luminal genes (e.g., NAT1, SLC39A6). DNA findings indicate that CelTIL response is significantly associated with TP53 mutations, proliferation, non-luminal signatures, and a distinct DNA-based subtype (DNADX cluster-3). Critically, low HER2DX ERBB2 mRNA, correlates with increased HER3-DXd activity, which is validated through in vivo patient-derived xenograft  models. This study proposes chemosensitivity determinants, DNA-based subtype classification, and low ERBB2 expression as potential markers for HER3-DXd activity in HER2-negative breast cancer.